C4 Therapeutics Inc.

CCCC

Held by 2 specialist biotech funds

Share on X

Fund Holdings

OrbiMed Advisors RA Capital Management

AI Signal

AI analyst context — unlock full analysis

Catalysts

No catalysts tracked.

Activist Filings

SC 13GRA Capital Management9.9%Oct 24, 2025

SC 13G/ARA Capital Management0.0%May 15, 2025

SC 13G

Position Details

OrbiMed AdvisorsNEWFeb 17, 2026

Shares: 1,404,902Value: $2.7M

**Signal Note: OrbiMed Initiates C4 Therapeutics (CCCC)** OrbiMed's $2.7M entry into CCCC signals confidence in the company's E3 ligase platform, likely driven by upcoming clinical catalysts in its lead program CFT7455 (a cereblon E3 ligase modulator for multiple myeloma) and pipeline expansion potential. The position size represents a measured entry typical of OrbiMed's early-stage biotech allocation, suggesting conviction in near-term data readouts rather than a major bet.

RA Capital ManagementNEWFeb 17, 2026

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

RNA2 funds IRON2 funds BCAX2 funds SION2 funds SPRY2 funds PRAX2 funds JANX2 funds ASND

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

# Signal Note: RA Capital Initiates CCCC Position RA Capital's $15.3M entry into C4 Therapeutics signals confidence in the company's targeted protein degradation platform, likely driven by upcoming clinical catalysts in its pipeline (e.g., PROTAC-based candidates in oncology). Kolchinsky's firm typically backs companies with differentiated mechanisms and clear path to value creation, suggesting conviction in C4's ability to execute versus competitors in the crowded degradation space.